JNJ-26481585

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Advanced or Refractory LeukemiaLymphomaMyelodysplastic SyndromesNeoplasms

Phase 1

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

TerminatedNCT00676728

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Advanced or Refractory Leukemia, Myelodysplastic Syndromes

Start: 2008-12-31End: 2011-09-30Updated: 2012-09-14

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

CompletedNCT00677105

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Lymphoma, Neoplasms

Start: 2007-08-31End: 2011-09-30Updated: 2012-09-17